Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up billions in quarterly sales. Its only real competitor in weight management is ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Steroid dealers using social media and beauty salons to sell cheap Chinese copies of weight-loss drugs, experts warn ...

On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Major pharmaceutical companies raised concerns about Ireland’s competitiveness, ahead of Donald Trump’s opening shots in early April which began the tariff war with the EU.

Alexa Bliss currently holds the WWE Women's Tag Team Championship alongside Charlotte Flair. The Queen and The Goddess made their presence felt on SmackDown this week.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Eli Lilly & Co ( ($LLY) ) has risen by 10.63%. Read on to learn why. Eli Lilly & Co has seen a notable increase in its stock price, rising ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...